Literature DB >> 34906291

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel.

Jennifer Kertes, Sharon Baruch Gez, Yaki Saciuk, Lia Supino-Rosin, Naama Shamir Stein, Miri Mizrahi-Reuveni, Anat E Zohar.   

Abstract

Israel experienced a new wave of coronavirus disease during June 2021, six months after implementing a national vaccination campaign. We conducted 3 discrete analyses using data from a large health maintenance organization in Israel to determine whether IgG levels of fully vaccinated persons decrease over time, describe the relationship between IgG titer and subsequent PCR-confirmed infection, and compare PCR-confirmed infection rates by period of vaccination. Mean IgG levels steadily decreased over the 6-month period in the total tested population and in all age groups. An inverse relationship was found between IgG titer and subsequent PCR-positive infection. Persons vaccinated during the first 2 months of the campaign were more likely to become infected than those subsequently vaccinated. The vaccinated group >60 years of age had lower initial IgG levels and were at greater risk for infection. The findings support the decision to add a booster vaccine for persons >60 years of age.

Entities:  

Keywords:  COVID-19; HMO; Israel; SARS-CoV-2; coronavirus disease; coronaviruses; epidemiology; health maintenance organization; immune response; infections; mRNA BNT162b2 vaccine; public health; respiratory infections; serologic tests; severe acute respiratory syndrome coronavirus 2; vaccination; vaccines; viruses; zoonoses

Mesh:

Substances:

Year:  2021        PMID: 34906291      PMCID: PMC8798683          DOI: 10.3201/eid2802.211834

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  15 in total

1.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

Authors:  David S Khoury; Deborah Cromer; Arnold Reynaldi; Timothy E Schlub; Adam K Wheatley; Jennifer A Juno; Kanta Subbarao; Stephen J Kent; James A Triccas; Miles P Davenport
Journal:  Nat Med       Date:  2021-05-17       Impact factor: 87.241

2.  COVID-19 vaccine impact in Israel and a way out of the pandemic.

Authors:  Eyal Leshem; Annelies Wilder-Smith
Journal:  Lancet       Date:  2021-05-05       Impact factor: 79.321

3.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.

Authors:  Noa Dagan; Noam Barda; Eldad Kepten; Oren Miron; Shay Perchik; Mark A Katz; Miguel A Hernán; Marc Lipsitch; Ben Reis; Ran D Balicer
Journal:  N Engl J Med       Date:  2021-02-24       Impact factor: 91.245

4.  Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors:  Juanjuan Zhao; Quan Yuan; Haiyan Wang; Wei Liu; Xuejiao Liao; Yingying Su; Xin Wang; Jing Yuan; Tingdong Li; Jinxiu Li; Shen Qian; Congming Hong; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Qing He; Zhiyong Li; Bin He; Tianying Zhang; Yang Fu; Shengxiang Ge; Lei Liu; Jun Zhang; Ningshao Xia; Zheng Zhang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079

5.  The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19.

Authors:  Wei Zhou; Xiaomao Xu; Zhigang Chang; He Wang; Xuefeng Zhong; Xunliang Tong; Taotao Liu; Yanming Li
Journal:  J Med Virol       Date:  2020-09-28       Impact factor: 20.693

6.  Not just antibodies: B cells and T cells mediate immunity to COVID-19.

Authors:  Rebecca J Cox; Karl A Brokstad
Journal:  Nat Rev Immunol       Date:  2020-10       Impact factor: 53.106

7.  COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.

Authors:  Pinja Jalkanen; Pekka Kolehmainen; Hanni K Häkkinen; Moona Huttunen; Paula A Tähtinen; Rickard Lundberg; Sari Maljanen; Arttu Reinholm; Sisko Tauriainen; Sari H Pakkanen; Iris Levonen; Arttu Nousiainen; Taru Miller; Hanna Välimaa; Lauri Ivaska; Arja Pasternack; Rauno Naves; Olli Ritvos; Pamela Österlund; Suvi Kuivanen; Teemu Smura; Jussi Hepojoki; Olli Vapalahti; Johanna Lempainen; Laura Kakkola; Anu Kantele; Ilkka Julkunen
Journal:  Nat Commun       Date:  2021-06-28       Impact factor: 14.919

8.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.

Authors:  Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Eileen Gallagher; Ruth Simmons; Simon Thelwall; Julia Stowe; Elise Tessier; Natalie Groves; Gavin Dabrera; Richard Myers; Colin N J Campbell; Gayatri Amirthalingam; Matt Edmunds; Maria Zambon; Kevin E Brown; Susan Hopkins; Meera Chand; Mary Ramsay
Journal:  N Engl J Med       Date:  2021-07-21       Impact factor: 91.245

View more
  12 in total

1.  Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?

Authors:  Masaaki Takeuchi; Akina Esaki; Yukie Higa; Akemi Nakazono
Journal:  PLoS One       Date:  2022-06-17       Impact factor: 3.752

2.  Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs.

Authors:  Neşe Saltoğlu; Harika Öykü Dinç; İlker İnanç Balkan; Günay Can; Doğukan Özbey; Ayşe Nur Beytur; Elif Keskin; Beyhan Budak; Okan Aydoğan; Bilgül Mete; Rıdvan Karaali; Sevgi Ergin; Bekir Kocazeybek
Journal:  Diagn Microbiol Infect Dis       Date:  2022-07-01       Impact factor: 2.983

3.  Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.

Authors:  Evangelos Terpos; Vangelis Karalis; Ioannis Ntanasis-Stathopoulos; Zoi Evangelakou; Maria Gavriatopoulou; Maria S Manola; Panagiotis Malandrakis; Despoina D Gianniou; Efstathios Kastritis; Ioannis P Trougakos; Meletios A Dimopoulos
Journal:  Biomedicines       Date:  2022-02-01

4.  Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity.

Authors:  Ewa Morgiel; Magdalena Szmyrka; Marta Madej; Agata Sebastian; Renata Sokolik; Iga Andrasiak; Maria Chodyra; Małgorzata Walas-Antoszek; Lucyna Korman; Jerzy Świerkot
Journal:  Vaccines (Basel)       Date:  2022-04-30

Review 5.  COVID-19 mRNA vaccines: Platforms and current developments.

Authors:  Gábor Tamás Szabó; Azita Josefine Mahiny; Irena Vlatkovic
Journal:  Mol Ther       Date:  2022-02-19       Impact factor: 12.910

Review 6.  Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters.

Authors:  Rachel M Burckhardt; John J Dennehy; Leo L M Poon; Linda J Saif; Lynn W Enquist
Journal:  J Virol       Date:  2021-11-24       Impact factor: 5.103

Review 7.  SARS-CoV-2 Omicron variant: Immune escape and vaccine development.

Authors:  Danyi Ao; Tianxia Lan; Xuemei He; Jian Liu; Li Chen; Daniel T Baptista-Hon; Kang Zhang; Xiawei Wei
Journal:  MedComm (2020)       Date:  2022-03-16

8.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.

Authors:  Peter B Gilbert; David C Montefiori; Adrian B McDermott; Ruben O Donis; Richard A Koup; Youyi Fong; David Benkeser; Weiping Deng; Honghong Zhou; Christopher R Houchens; Karen Martins; Lakshmi Jayashankar; Flora Castellino; Britta Flach; Bob C Lin; Sarah O'Connell; Charlene McDanal; Amanda Eaton; Marcella Sarzotti-Kelsoe; Yiwen Lu; Chenchen Yu; Bhavesh Borate; Lars W P van der Laan; Nima S Hejazi; Chuong Huynh; Jacqueline Miller; Hana M El Sahly; Lindsey R Baden; Mira Baron; Luis De La Cruz; Cynthia Gay; Spyros Kalams; Colleen F Kelley; Michele P Andrasik; James G Kublin; Lawrence Corey; Kathleen M Neuzil; Lindsay N Carpp; Rolando Pajon; Dean Follmann
Journal:  Science       Date:  2021-11-23       Impact factor: 63.714

9.  Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study.

Authors:  Ramandip Grewal; Sophie A Kitchen; Lena Nguyen; Sarah A Buchan; Sarah E Wilson; Andrew P Costa; Jeffrey C Kwong
Journal:  BMJ       Date:  2022-07-06

10.  Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines-Effectiveness in Delta Variant Breakthrough Infections.

Authors:  Gema Fernández-Rivas; Jaume Barallat; Bibiana Quirant-Sánchez; Victoria González; María Doladé; Eva Martinez-Caceres; Monica Piña; Joan Matllo; Ignacio Blanco; Pere-Joan Cardona
Journal:  Viruses       Date:  2022-06-24       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.